Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data
2024年8月13日 - 11:50PM
AllPennyStocks.com
A California-based biotech company is finding
early success on Tuesday after the company announced positive
preliminary data of Vebreltinib in patients with non-CNS met
fusion...
To read the full story on AllPennyStocks.com, click
here.
Apollomics (NASDAQ:APLMW)
過去 株価チャート
から 10 2024 まで 11 2024
Apollomics (NASDAQ:APLMW)
過去 株価チャート
から 11 2023 まで 11 2024
